Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
設定
言語
日本
通貨
USD
テーマ
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
株式のランク #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
株価
$0.0416118
時価総額
$12.78M
変化（1日）
1.72%
変化（1年）
-22.01%
国
AU
取引 Noxopharm Limited (NOX)

カテゴリー

Healthcare
Noxopharm Limited（NOX）の発行済株式数
December 2025 時点の発行済株式数 292.24M
Noxopharm Limited の最新の財務報告および株価によると、現在の発行済株式数は 292.24M です。June 2024 の終わりには、同社は 292.26M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Noxopharm Limited（NOX）の発行済株式数の履歴（2016 ～ 2026）
各年末時点の発行済株式数
年 発行済株式数 変化
2026 (TTM) 292.24M -0.08%
2025 292.47M 0.07%
2024 292.26M 0.01%
2023 292.24M 0.35%
2022 291.22M 10.37%
2021 263.85M 90.70%
2020 138.36M 0.15%
2019 138.15M 16.06%
2018 119.03M 35.93%
2017 87.57M 160.94%
2016 33.56M 0.00%
類似企業や競合他社の発行済株式数
企業 発行済株式数 差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 1,422.00%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -13.12%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -64.79%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -34.99%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 65.47%
AU